Latest Regulatory News

29Metals has successfully moved its application for a new tailings storage facility at Capricorn Copper into detailed assessment, marking a critical step toward restarting operations sustainably.

Fortescue Ltd reported a solid FY25 with record iron ore shipments and a strong profit, while making significant strides in its decarbonisation agenda including renewable energy projects and green metal production.

29Metals Limited has reversed a significant loss to report a $35.3 million net profit for the first half of 2025, driven by stronger production at Golden Grove and improved metal prices, while Capricorn Copper remains suspended amid ongoing water and regulatory challenges.

Holista Colltech has inked a binding supply and development agreement with US-based Regenerex Pharma to exclusively supply proprietary ovine collagen for advanced wound care products, targeting the lucrative US market initially with plans for global expansion.

Acusensus Limited reported a robust FY25 with 20% revenue growth and a significant 84% jump in total contract value, setting the stage for an ambitious FY26 forecast of up to 41% revenue increase.

Firebrick Pharma has secured an exclusive licensing agreement with Innorini Pte Ltd to distribute Nasodine products across Singapore, Malaysia, Brunei, and Mauritius, aiming to reduce marketing expenses and broaden market access.

Vulcan Steel Limited reported a 10.9% revenue decline in FY25 alongside a 24.1% drop in adjusted EBITDA, while announcing a fully underwritten NZ$96 million equity raise to fund the acquisition of Roofing Industries Limited. The deal marks Vulcan’s strategic entry into the New Zealand steel roofing and cladding market with expected earnings accretion and no change to its dividend policy.

Imricor Medical Systems reports significant regulatory approvals and clinical trial progress, positioning itself as a disruptive force in the growing electrophysiology market. With a strengthened commercial pipeline and solid cash reserves, the company is poised for a pivotal growth phase.

Imricor Medical Systems reported a sharp 52% revenue decline and a 92% increase in net loss for H1 2025, offset by a $42.8 million equity raise boosting liquidity. The company is investing heavily in European sales and clinical trials while pursuing FDA approval.

Pointerra Limited reported a strong FY25 with revenue up 45% to A$11 million and a significant reduction in net loss by 68%, driven by scalable SaaS growth and key US contract wins.

Cedar Woods Properties Limited delivered a robust FY25 with a 19% increase in net profit, underpinned by a diversified project portfolio and favourable market conditions. The company signals continued growth with a 10% NPAT guidance for FY26, supported by strong presales and strategic partnerships.

AUB Group Limited has reported a robust FY25 financial performance, highlighted by a 171% increase in underlying net profit after tax and a 15.2% rise in total dividends. Strategic acquisitions and organic growth across divisions underpin the company’s strong momentum.